Mitigating the toxic effects of anticancer immunotherapy.
about
Recent advances in the management of Hodgkin lymphomaViro-immune therapy: A new strategy for treatment of pancreatic cancerPembrolizumabAntibody Therapies in Cancer.Targeting CD8+ T-cell tolerance for cancer immunotherapy.Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapiesAn update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers.PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerationsImmune modulation for cancer therapy.Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells.Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.PD-1/PD-L1 inhibitors.Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptorReporter nanoparticle that monitors its anticancer efficacy in real time.Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cellsCurrent Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapyPhosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.Targeting the immune system to treat lung cancer: rationale and clinical experience.Safety of pembrolizumab for the treatment of melanoma.Prospects and progress of immunotherapy for bladder cancer.Optimizing tumor immune response through combination of radiation and immunotherapy.Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.Looking beyond the cancer cell for effective drug combinations.The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities.Immunotherapy for breast cancer: past, present, and future.Immune checkpoint inhibitors in lung cancer: past, present and future.Adapting Cancer Immunotherapy Models for the Real World.PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.Metastatic melanoma and immunotherapyObesity and cancer immunotherapy toxicity.Immuno-Oncology: The Third Paradigm in Early Drug Development.Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.Post-nano strategies for drug delivery: Multistage porous silicon microvectors.Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.Ipilimumab-associated colitis or refractory Clostridium difficile infection?
P2860
Q26751214-F5B53997-569A-44BC-A05D-90583A08E9ADQ26774641-CB9372B6-7109-4F3B-9AF7-082172BC51A6Q26796435-A726D105-AC4E-47E2-8CEE-C41C48F9213AQ31104000-2EA98CE7-D1FD-41AB-A202-5088981537ACQ34432692-283FA3E8-7895-44B1-9579-36644D7107D9Q34458339-C8E20487-0953-49DA-A8BA-866BB16F622CQ34511672-5F31152F-884A-44E7-8983-7ADE8051E7B1Q34538075-1BE8233F-D856-43A9-9B3D-1CF699EDEE81Q34644359-C9F8570E-1012-412B-A560-7D32E4FA79A9Q34667662-B3C40506-75B3-4AC1-B32A-90AC8A038741Q34686944-8C25949B-381D-4028-A3C2-DB91D649948CQ35071484-C4CE01A6-54F8-4649-872C-6A41AC13636DQ35572171-91B2784D-35A2-408D-9756-BD1BA10F6508Q35893753-350FB9AF-BC16-4EF0-BE76-BDEA1A1767CDQ35979344-8AB8C962-25EF-4279-BBA3-0365F3B85EC5Q36821565-A809A70B-C396-4765-86E5-989C33C16190Q37131014-78BFEA40-31C3-48C0-B76F-F3185F89E4B0Q37268962-323DC9C3-BDA9-4125-88BD-0E10492718D7Q37629874-F4600386-8EBC-4CDB-BF13-8280741F117BQ38285175-54E03471-86C1-4C8D-82EA-AC3042A835AFQ38397629-857D2FA6-8DEE-4360-90F7-8E7625D61CDDQ38451331-A328AEC5-2EF0-4672-AB40-80D9437D4D9BQ38612818-EEF02441-32FA-4A32-843B-40B97CFAEE2EQ38614781-0B9D4C39-511D-4B68-9632-3724F28E8AEBQ38636284-4D1204ED-F69E-4C28-9E9F-5B4BA4974BF5Q38722809-1AF05AC1-4CFB-4825-B3C9-AB323160A60FQ38728970-4FD91A58-3E58-4288-B591-2876D5A2AD86Q38753386-9C65CCDD-6F5B-4495-B54A-B33D08F65728Q38753955-5DA8FDAA-A000-4A52-B79B-5540BA0E1D0DQ38787696-4FDC3A3C-A9B8-4268-B867-47C5C6F910FFQ38791209-0D89C544-CFBD-482C-87B5-381CE525DF82Q38815212-A65756A9-E419-4781-B6C7-695C3535B3BDQ38838649-CD37164A-FB82-4C6C-A3D3-C83D5F6E3C78Q38901338-C3A7A186-20A2-4EA5-A2FB-1A3441A85C81Q38925720-78CD1E55-3D60-43D8-9217-50FA51B694D9Q39044147-2A8037C4-C60B-425F-AFE3-887B7839A079Q39159356-33F33B53-19A5-4B54-906C-ED5D458CF911Q39410383-D89A8808-8830-489B-8918-E0EFC5730EFAQ40340021-6E8D3228-C94C-43BE-BA1D-280EC8EEB607Q41110062-8669F7D3-F3D6-480F-851A-FA6719A2C8CB
P2860
Mitigating the toxic effects of anticancer immunotherapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Mitigating the toxic effects of anticancer immunotherapy.
@en
type
label
Mitigating the toxic effects of anticancer immunotherapy.
@en
prefLabel
Mitigating the toxic effects of anticancer immunotherapy.
@en
P2860
P1476
Mitigating the toxic effects of anticancer immunotherapy.
@en
P2093
Robert H Vonderheide
Tara C Gangadhar
P2860
P356
10.1038/NRCLINONC.2013.245
P407
P577
2014-01-21T00:00:00Z